News
BriaCell Therapeutics Corporation announces updated phase 2 data of Bria-IMT, shows survival advantage over Trodelvy in metastatic breast cancer: Philadelphia & Vancouver, British ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback